Your session is about to expire
← Back to Search
Pembrolizumab + Radiotherapy for Liver Cancer
Study Summary
This trial is testing whether a combination of two cancer treatments is more effective than one of the treatments alone in people with advanced liver cancer who have progressed after treatment with another drug.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2024 Phase 2 trial • 57 Patients • NCT03004183Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You experienced bleeding from the esophagus or stomach within the past 3 months before joining the study.You have received a specific type of radiation therapy called radioembolization or other selective internal radiotherapy treatment to the liver in the past.You are currently taking part in another clinical trial or have recently received experimental treatment or used an investigational device.You are allergic to pembrolizumab or any of its ingredients.You have a history of lung problems that are not caused by an infection.You have mental health or substance abuse problems that might make it difficult for you to follow the trial's rules and instructions.You have a history of serious heart problems that are currently active or unstable.You have a liver tumor that cannot be treated with a specific type of radiation therapy, or you have previously received radiation therapy in the upper abdomen in amounts that are higher than what is considered safe.The tumor has not spread directly to the stomach, duodenum, small bowel, large bowel, or diaphragm.You have already tried a different treatment for advanced liver cancer after sorafenib, or you have received radiation therapy in the area where the new treatment would be given.Your condition has gotten worse after being treated with sorafenib for at least 8 weeks, even with breaks or lower doses.
- Group 1: Pembrolizumab and Stereotactic Body Radiotherapy (SBRT)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
To what maladies is Pembrolizumab typically applied as a treatment?
"Pembrolizumab is typically endorsed to treat malignant neoplasms, yet it can also be utilized to manage unresectable melanoma, microsatellite instability-high conditions and the advancement of diseases after chemotherapy."
Does taking Pembrolizumab pose a substantial risk to patients?
"Despite not yet having any efficacy data, the safety of Pembrolizumab was estimated to be a 2 on our team's scale, due to Phase 2 trial results."
How many participants are currently engaged in the clinical experiment?
"Affirmative. Clinicaltrials.gov records indicate that this experiment, initiated on February 15th 2018, is currently recruiting participants. 30 individuals are being sought after from a single medical centre."
Does this experiment accept new participants at the current time?
"This clinical trial is presently enrolling patients as per information hosted on clinicaltrials.gov, with the initial post date of February 15th 2018 and last update occurring December 31st 2021."
Have researchers conducted any previous investigations related to Pembrolizumab?
"Currently, there are 961 medically-approved studies into the efficacy of Pembrolizumab with 122 having progressed to Phase 3. Though Houston is a major site for these trials, one can find 35727 different locations conducting clinical research on this drug."
Share this study with friends
Copy Link
Messenger